Qiagen NV (QGEN)
42.28
-0.35
(-0.82%)
USD |
NYSE |
Nov 14, 12:24
Qiagen Enterprise Value: 9.986B for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 9.986B |
| November 12, 2024 | 10.12B |
| November 11, 2024 | 10.30B |
| November 08, 2024 | 10.24B |
| November 07, 2024 | 10.32B |
| November 06, 2024 | 10.26B |
| November 05, 2024 | 10.28B |
| November 04, 2024 | 10.21B |
| November 01, 2024 | 10.09B |
| October 31, 2024 | 9.868B |
| October 30, 2024 | 9.899B |
| October 29, 2024 | 9.808B |
| October 28, 2024 | 9.801B |
| October 25, 2024 | 9.746B |
| October 24, 2024 | 9.757B |
| October 23, 2024 | 9.872B |
| October 22, 2024 | 9.892B |
| October 21, 2024 | 9.872B |
| October 18, 2024 | 10.07B |
| October 17, 2024 | 9.999B |
| October 16, 2024 | 10.11B |
| October 15, 2024 | 10.26B |
| October 14, 2024 | 10.31B |
| October 11, 2024 | 10.27B |
| October 10, 2024 | 10.13B |
| Date | Value |
|---|---|
| October 09, 2024 | 10.39B |
| October 08, 2024 | 10.19B |
| October 07, 2024 | 10.14B |
| October 04, 2024 | 10.19B |
| October 03, 2024 | 10.19B |
| October 02, 2024 | 10.37B |
| October 01, 2024 | 10.49B |
| September 30, 2024 | 10.64B |
| September 27, 2024 | 10.57B |
| September 26, 2024 | 10.52B |
| September 25, 2024 | 10.31B |
| September 24, 2024 | 10.48B |
| September 23, 2024 | 10.39B |
| September 20, 2024 | 10.49B |
| September 19, 2024 | 10.64B |
| September 18, 2024 | 10.66B |
| September 17, 2024 | 10.66B |
| September 16, 2024 | 10.86B |
| September 13, 2024 | 10.81B |
| September 12, 2024 | 10.64B |
| September 11, 2024 | 10.70B |
| September 10, 2024 | 10.71B |
| September 09, 2024 | 10.71B |
| September 06, 2024 | 10.40B |
| September 05, 2024 | 10.40B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
8.416B
Minimum
Dec 26 2019
14.04B
Maximum
Sep 02 2021
11.26B
Average
11.03B
Median
Jun 03 2020
Enterprise Value Benchmarks
| LENZ Therapeutics Inc | 783.65M |
| Oruka Therapeutics Inc | -- |
| Boston Scientific Corp | 139.46B |
| uniQure NV | -52.67M |
| ProQR Therapeutics NV | 226.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -183.46M |
| Revenue (Quarterly) | 496.35M |
| Total Expenses (Quarterly) | 656.70M |
| EPS Diluted (Quarterly) | -0.83 |
| Gross Profit Margin (Quarterly) | 7.00% |
| Profit Margin (Quarterly) | -36.96% |
| Earnings Yield | 0.75% |
| Operating Earnings Yield | 1.76% |
| Normalized Earnings Yield | 1.550 |